Continuous heart monitoring to evaluate treatment effects in pulmonary hypertension
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 976 KB, PDF-dokument
Objectives To assess treatment effects before and after the escalation of specific PH treatments using continuous heart monitoring with a Reveal LINQ loop recorder.
Methods Patients were compared before and after treatment escalation. Treatment escalation was defined as an additional pulmonary arterial hypertension (PAH) drug, pulmonary endarterectomy, percutaneous balloon angioplasty or bilateral lung transplantation. Specifically, changes in heart rate variability (HRV), heart rate (HR) and physical activity were assessed.
Results In this prospective study, 41 patients (27 with PAH and 14 with chronic thromboembolic pulmonary hypertension (CTEPH)) were enrolled. Among them, 15 (36.6%) patients underwent PH treatment escalation. Prior to escalation, patients were monitored for a median of 100 (range: 68–100) days and after therapy escalation for a median duration of 165 (range: 89–308) days. In the escalation group, there was a significant increase in HRV, physical activity indexed by daytime HR and a significant decrease in nighttime HR assessed at baseline and after treatment escalation in both the PAH and CTEPH groups. This was paralleled by significant improvements in WHO functional class, 6-min walking distance and N-terminal pro-b-type natriuretic peptide.
Conclusions This is the first study to demonstrate an association between specific PH therapies and changes in HRV, HR nighttime and physical activity. This indicates the potential of continuous monitoring in the evaluation of treatment effects in PH.
Originalsprog | Engelsk |
---|---|
Artikelnummer | e002710 |
Tidsskrift | Open Heart |
Vol/bind | 11 |
Udgave nummer | 1 |
Antal sider | 9 |
ISSN | 2398-595X |
DOI | |
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:
The study was supported by the Heart Centre Research Council of Rigshospitalet and an investigator-initiated study research grant from Janssen-Cilag. The study was conducted without any interference or financial support from the manufacturer of the ILR used.
Funding Information:
Mads \u00D8rb\u00E6k Andersen has nothing to declare. S\u00F8ren Z\u00F6ga Diederichsen has received consultancy fees from Bristol Myers Squibb/Pfizer, Vital Beats and Acesion Pharma, speaker fees from Bristol Myers Squibb, and travel grants from Abbott. Jesper Hastrup Svendsen is a member of an advisory board for Medtronic and has received speaker fees and research grants from Medtronic. J\u00F8rn Carlsen is a member of an advisory board for Merck and has received institutional research grants and institutional speaker fees.
Publisher Copyright:
© 2024 BMJ Publishing Group. All rights reserved.
ID: 392570944